Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Sells 588 Shares of The Clorox Company (NYSE:CLX)

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group decreased its stake in shares of The Clorox Company (NYSE:CLX) by 7.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,915 shares of the company’s stock after selling 588 shares during the period. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group’s holdings in Clorox were worth $1,018,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in CLX. Norges Bank purchased a new position in shares of Clorox in the fourth quarter worth approximately $259,041,000. FMR LLC grew its position in shares of Clorox by 75.4% during the fourth quarter. FMR LLC now owns 1,361,758 shares of the company’s stock worth $221,163,000 after purchasing an additional 585,526 shares in the last quarter. KBC Group NV grew its position in shares of Clorox by 688.7% during the first quarter. KBC Group NV now owns 587,679 shares of the company’s stock worth $86,535,000 after purchasing an additional 513,171 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Clorox by 549.8% in the fourth quarter. Marshall Wace LLP now owns 542,726 shares of the company’s stock worth $88,144,000 after purchasing an additional 459,203 shares during the last quarter. Finally, ExodusPoint Capital Management LP raised its position in shares of Clorox by 187.9% during the 4th quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company’s stock valued at $113,508,000 after buying an additional 456,114 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Insider Activity at Clorox

In other Clorox news, Director Pierre R. Breber purchased 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director owned 4,000 shares of the company’s stock, valued at approximately $546,280. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.57% of the stock is currently owned by company insiders.

Clorox Stock Performance

NYSE CLX traded up $0.34 during trading on Friday, reaching $129.60. The company’s stock had a trading volume of 78,898 shares, compared to its average volume of 1,594,330. The firm has a market cap of $15.97 billion, a price-to-earnings ratio of 23.27, a P/E/G ratio of 3.14 and a beta of 0.51. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The Clorox Company has a twelve month low of $117.35 and a twelve month high of $171.37. The business’s fifty day moving average price is $127.49 and its 200-day moving average price is $141.59.

Clorox (NYSE:CLX) last released its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. Clorox’s revenue was down 8.0% compared to the same quarter last year. During the same period last year, the business posted $1.71 EPS. As a group, analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on CLX. JPMorgan Chase & Co. lowered their target price on shares of Clorox from $151.00 to $144.00 and set a “neutral” rating for the company in a report on Tuesday, May 6th. Citigroup reissued a “neutral” rating and set a $135.00 target price (down from $140.00) on shares of Clorox in a research note on Tuesday. Barclays set a $119.00 price target on Clorox and gave the stock an “underweight” rating in a research report on Tuesday. Evercore ISI set a $140.00 price objective on Clorox and gave the company an “underperform” rating in a research report on Tuesday, May 6th. Finally, Wells Fargo & Company dropped their price objective on Clorox from $142.00 to $135.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 9th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $145.17.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.